Browsing by Author "Alicikus, ZA"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A Promising, Novel Radiosensitizer Nanodrug Complex for Oral Cavity Cancer: Cetuximab and Cisplatin-Conjugated Gold Nanoparticles
    Sürer, SI; Elçitepe, TB; Akçay, D; Daskin, E; Kocal, GÇ; Alicikus, ZA; Eskiizmir, G; Yapici, K; Basbinar, Y
    Background: Nanomedicine has provided promising tools for the imaging, diagnosis, and treatment of cancer. Gold nanoparticles (GNPs) may be useful in enhancing the efficacy of radiotherapy, such as radiosensitization, in cancer therapy. Aims: To develop a nanodrug complex containing cetuximab (C225, CTX) and cisplatin (CDDP) conjugated with GNPs and to investigate its cytotoxic effects on oral cavity cancer cells when combined with radiotherapy. Study Design: In vitro cell culture study. Methods: The GNPs were synthesized and successfully conjugated with cetuximab and cisplatin. Cell viability was monitored by the xCELLigence real-time cell analysis (RTCA) single-plate (SP) system in GNP-treated UPCI-SCC-131 cells for 48 hours. Cells with/without GNPs were irradiated with 6 MV X-rays, and colony formation was assayed to investigate the long-term effects of GNPs and the nanodrug complex after irradiation on radiotherapy-resistant oral cavity cancer cells. Results: The GNPs entered the tumor cells, and GNP-CDDP (P<.0001) and GNP-CDDP-CTX (P<.0001) were shown to cause a decrease in cell viability. GNP and GNP-CTX combined with radiotherapy led to greater reduction on UPCI-SCC-131 colony numbers, than radiation alone (P=.0369) and radiation with free CTX, with sensitizing enhancement ratios of 1 : 2 and 1 : 9, respectively. Conclusion: The cetuximab and cisplatin-conjugated gold nanodrug complex has a great potential to increase cytotoxicity and overcome resistance to radiotherapy, in the treatment of oral cavity cancer.
  • No Thumbnail Available
    Item
    Patterns of care for lung cancer in radiation oncology departments of Turkey
    Demiral, A; Alicikus, ZA; Ugur, V; Karadogan, I; Yoney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Ozyigit, G; Ozkan, L; Kilciksiz, S; Koca, S; Caloglu, M; Yavuz, A; Caglar, H; Beyzad-eoglu, M; Igdem, S; Serin, M; Kaplan, B; Koc, M; Korkmaz, E; Celik, OK; Kinay, M
  • No Thumbnail Available
    Item
    PATTERNS OF CARE FOR LUNG CANCER IN RADIATION ONCOLOGY DEPARTMENTS OF TURKEY
    Demiral, AN; Alicikus, ZA; Ugur, VI; Karadogan, I; Yöney, A; Andrieu, MN; Yalman, D; Pak, Y; Aksu, G; Özyigit, G; Özkan, L; Kilçiksiz, S; Koca, S; Çaloglu, M; Yavuz, AA; Çaglar, HB; Beyzadeoglu, M; Igdem, S; Serin, M; Kaplan, B; Koç, M; Korkmaz, E; Karakoyun-Çelik, Ö; Dinçer, S; Kinay, M
    Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were >= IB disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. (c) 2008 Elsevier Inc.